Brain Tumor Life Insurance Underwriting Guide

The Central Underwriting Idea

"Brain tumor" is not one underwriting diagnosis. A small WHO Grade 1 meningioma that was completely removed — or has remained stable on serial MRI without symptoms — can present a very different mortality risk from a diffuse glioma, recurrent high-grade tumor, metastatic brain disease or glioblastoma.

For life insurance underwriting, the most important facts are the exact tumor type, WHO grade or other pathology classification, location, size, whether it was completely removed, residual tumor on MRI, recurrence or growth, seizures or neurological deficits, treatment, molecular markers when relevant, and time with stable follow-up. Unlike many cancers, primary brain tumors generally are not evaluated with a conventional Stage I–IV system; pathology, grade, location, resectability and molecular biology often carry more meaning.

Benign or malignant? Pathology and exact diagnosis: meningioma, vestibular schwannoma, pituitary tumor/PitNET, glioma, glioblastoma, oligodendroglioma, ependymoma, metastasis, or another CNS tumor.
How aggressive is it? WHO grade, histology and, for diffuse gliomas, molecular findings such as IDH status and 1p/19q codeletion.
Was it completely removed? Operative note, pathology, gross-total vs subtotal resection and postoperative MRI.
Is anything left or growing? Serial MRI/CT, residual size, interval growth, recurrence and next planned imaging.
What functional risk remains? Seizures, weakness, speech/cognitive change, headaches, hydrocephalus, vision/hearing/balance deficits and driving restrictions.
What treatment was required? Observation, surgery, stereotactic radiosurgery, radiation, chemotherapy, targeted therapy or other systemic treatment.

Can Someone With a Brain Tumor History Qualify for Life Insurance?

Yes. Benign brain tumors are often insurable, and some favorable histories can ultimately receive ordinary or near-ordinary pricing. Malignant primary brain tumors are much more difficult, but the answer still depends on the exact diagnosis. A low-grade IDH-mutated glioma and an IDH-wildtype glioblastoma do not have the same prognosis, treatment course or underwriting outlook.

The most favorable underwriting profile usually involves a clearly benign tumor, complete treatment or long-term radiographic stability, no recurrence or growth, no seizures, no meaningful neurological deficits and consistent specialist follow-up. A tumor found incidentally can be favorable when its type, size and serial imaging are reassuring. "Benign," however, does not mean irrelevant: even a noncancerous mass can cause pressure, seizures, hearing loss, visual loss or other serious complications because of its location inside the skull.

The Brain-Tumor Underwriting Sweet Spot

WHO Grade 1 meningioma, especially when completely resected with no recurrence on follow-up MRI and no neurological residuals.
Small, asymptomatic meningioma under observation with several years of documented MRI stability and no seizures, edema or neurological deficit.
Unilateral vestibular schwannoma (acoustic neuroma) that is completely treated or stable on serial MRI, with no brainstem compression or significant neurological complications.
Small pituitary-region tumor/PitNET with stable imaging, controlled hormonal effects, no invasive behavior and no serious visual or neurological impairment.
Across benign tumors: no progressive imaging, no unresolved hydrocephalus, no recurrent seizures, no major cognitive/motor impairment and reliable neurosurgical/neurological follow-up.

The First Divide: Benign vs Malignant — Then Keep Going

Benign meningioma, vestibular schwannoma and pituitary-region tumors can still differ substantially from one another. Among malignant gliomas, WHO grade and molecular features such as IDH mutation and 1p/19q codeletion can materially refine prognosis. The exact pathology should lead the underwriting discussion.

Benign Brain Tumors: Often the Best Underwriting Opportunity

NCI describes benign brain and spinal-cord tumors as noncancerous growths that generally do not invade or metastasize like malignant tumors, but they can still press on important structures and can recur. Underwriting therefore focuses not merely on whether the word "benign" appears in the chart, but on location, size, symptoms, treatment, residual tumor and long-term imaging behavior.

WHO Grade 1 meningioma — Most common meningioma; generally slow growing, sometimes observed, sometimes removed. Underwriting emphasis: grade, complete vs subtotal resection, residual tumor, edema, seizures, MRI stability, recurrence and neurological function.
Vestibular schwannoma / acoustic neuroma — Usually benign and slow growing, arising from the hearing/balance nerve; may be observed, radiated or removed. Underwriting emphasis: tumor size, brainstem effect, treatment, MRI stability, unilateral vs bilateral disease, hearing/balance/facial nerve residuals and NF2.
Pituitary adenoma / PitNET — Sellar tumor that may be hormonally active or inactive. Underwriting emphasis: size, invasion, visual fields, endocrine effects, treatment, hormone control and stability — the label alone should not determine risk.
Craniopharyngioma — Usually low-grade/benign but near pituitary/optic structures; treatment can create endocrine and visual consequences. Underwriting emphasis: completeness of treatment, recurrence, pituitary hormone replacement, vision, hypothalamic effects and functional status.
Other benign/low-grade CNS tumors — Includes selected schwannomas, hemangioblastomas, pilocytic tumors and other rare entities. Underwriting emphasis: exact pathology, genetic syndrome if any, location, residual disease, recurrence, neurological effects and imaging trend.

Meningioma: The Classic Favorable Brain-Tumor Case

Meningiomas arise from the meninges rather than brain tissue itself. NCI groups them into WHO Grades 1, 2 and 3. Grade 1 is the most common and generally slow growing; selected asymptomatic tumors may be followed with active surveillance, while resectable tumors can often be removed surgically. Grade 2 and Grade 3 meningiomas have greater recurrence and growth potential and usually require more aggressive treatment.

For underwriting, a pathology-confirmed Grade 1 meningioma with complete resection, clean postoperative imaging and several years without recurrence is one of the strongest possible brain-tumor histories. A small untreated Grade 1 meningioma may also become favorable when serial MRI demonstrates stability and the applicant remains asymptomatic. Subtotal resection, persistent tumor growth, repeated surgeries, radiation, seizures, cerebral edema or neurological deficits make the case more conservative.

Grade 1, gross-total resection, clean MRI follow-up, no seizures/deficits — Potentially favorable after an appropriate observation period; strongest benign-tumor profile.
Small incidental Grade 1 tumor, no treatment, serial MRI stable for years — Potential consideration in selected cases; stability and absence of symptoms are central.
Subtotal resection or known residual tumor — More conservative; amount of residual disease, growth rate and follow-up interval matter.
Grade 2 atypical meningioma — Higher recurrence risk; usually requires longer stability and closer review.
Grade 3/anaplastic or recurrent aggressive meningioma — Treated much more like malignant CNS disease; often difficult for traditional underwriting.

Vestibular Schwannoma (Acoustic Neuroma)

A vestibular schwannoma is a benign, usually slow-growing tumor of the Schwann cells surrounding the hearing and balance nerves. NIH/NIDCD notes that management may include observation, surgery or radiation depending on tumor size, growth, symptoms, hearing status and overall health. Large tumors can compress the brainstem or cerebellum, while treatment itself can affect hearing, balance or facial-nerve function.

For life underwriting, the best story is a unilateral, sporadic tumor that is small and stable or has been successfully treated, with no regrowth and no significant neurological residuals. Bilateral vestibular schwannomas raise a different question because they are strongly associated with NF2-related schwannomatosis, which may involve multiple CNS tumors and therefore requires broader review.

Pituitary Tumors: Do Not Let the New Name Mislead the Underwriter

Pituitary adenomas are increasingly described as pituitary neuroendocrine tumors (PitNETs). Munich Re has highlighted that this changing terminology can create insurance-definition confusion. From a life-underwriting standpoint, the practical questions remain tumor size, local invasion, hormonal secretion, visual-field effects, treatment, recurrence and control of any endocrine disorder. A small, stable, noninvasive tumor with well-controlled hormones is very different from an invasive macro-tumor with persistent endocrine or visual complications.

A terminology change is not automatically a mortality change. When older records say "pituitary adenoma" and newer records say "PitNET," the underwriter should reconcile the pathology and clinical behavior rather than assume the new word "tumor" or neuroendocrine classification means a newly aggressive cancer.

Malignant Gliomas: Grade and Molecular Biology Matter

Diffuse gliomas arise from glial cells and range from relatively slower-growing tumors to highly aggressive glioblastoma. Modern CNS classification uses both histology and molecular findings. NCI notes that IDH1 or IDH2 variants are strong favorable prognostic factors in diffuse gliomas, while oligodendroglioma is defined by an IDH mutation together with 1p/19q codeletion. These molecular findings are therefore not academic details; they can materially change prognosis and the underwriting narrative.

IDH-mutated lower-grade astrocytoma — Favorable molecular marker relative to IDH-wildtype disease, though it may still recur/progress over time. Potential future consideration only after treatment/stability; exact grade, resection, residual tumor, seizures and long-term MRI trend are essential.
Oligodendroglioma, IDH-mutated and 1p/19q-codeleted — Generally more favorable than many other infiltrating gliomas, but still malignant CNS disease; a long disease-free/stable interval and complete documentation are needed.
High-grade astrocytoma — More aggressive biology, often requiring surgery plus radiation/systemic therapy. Usually prolonged postponement or decline during active/recent disease; recurrence risk dominates.
Glioblastoma, IDH-wildtype — Highly aggressive; standard treatment often includes surgery, radiation and temozolomide. Typically extremely difficult for traditional fully underwritten life insurance, especially during active/recent disease.
Brain metastasis from another cancer — Underwritten primarily as metastatic systemic cancer; generally represents advanced disease and is usually uninsurable in traditional markets.

Glioblastoma: The Opposite End of the Spectrum

Glioblastoma is one of the most aggressive primary malignant brain tumors. NCI describes the standard approach for newly diagnosed glioblastoma as maximal safe surgery when feasible followed by radiation with temozolomide and then additional temozolomide. Prognosis is affected by factors including age, functional status, extent of resection and molecular findings such as MGMT promoter methylation, but recurrence remains common.

For life underwriting, glioblastoma is generally not a near-term impaired-risk opportunity. Active disease, current chemotherapy/radiation, residual or recurrent tumor and limited disease-free time usually make traditional fully underwritten coverage unavailable. The correct brokerage strategy is to identify the exact diagnosis and current status rather than trying to analogize glioblastoma to a favorable benign brain tumor.

Gross-Total Resection, Residual Tumor and Serial MRI

For both benign and malignant CNS tumors, "surgery completed" does not answer the underwriting question. The operative report and postoperative MRI should clarify whether there was gross-total resection, subtotal resection or biopsy only. NCI identifies the amount of tumor remaining after surgery as an important prognostic and treatment factor.

A residual tumor may remain stable for years, particularly with selected benign lesions, but it creates an ongoing surveillance issue. Underwriters will want the size of residual disease, serial imaging dates, whether there has been interval growth, whether additional treatment is planned and whether the residual tumor causes edema, seizures or neurological deficits.

Serial MRI is often the brain-tumor equivalent of a lab trend. One isolated MRI is a snapshot. Several years of stable imaging can transform the underwriting story for a benign or low-grade tumor because it demonstrates actual behavior over time.

Seizures and Neurological Residuals Can Become Separate Underwriting Risks

A tumor-related seizure is important for two reasons: it can signal cortical irritation or active disease, and recurrent seizures can create additional accident and mortality risk even after the tumor is treated. NAILBA's field guide emphasizes that when seizures are caused by a brain tumor, the underlying tumor may matter more than the seizure diagnosis itself.

The submission should identify whether seizures occurred before treatment, whether they continued afterward, the date of the last seizure, antiseizure medication, EEG findings if relevant, driving status and any functional restrictions. Other residuals — weakness, aphasia, cognitive impairment, hydrocephalus, visual-field loss, facial weakness, hearing loss or balance impairment — should be documented separately because they can influence the offer even when the tumor is stable.

Illustrative Underwriting Timing and Outcomes

The following framework is educational rather than a carrier quote. Current public carrier materials confirm that brain-tumor and non-skin-cancer histories commonly require an APS and individualized review.

Completely resected WHO Grade 1 meningioma; years of clean MRIs; no seizures/deficits — Potentially favorable; ordinary or modestly rated consideration may be possible depending on carrier and elapsed stability.
Small untreated benign meningioma stable on serial MRI for years — Potential case-by-case consideration; long-term stability is the main favorable evidence.
Treated/stable unilateral vestibular schwannoma — Often more favorable than malignant brain tumors; outcome depends on residuals and stability.
Lower-grade IDH-mutated glioma after treatment, no progression — Usually requires substantial disease-free/stable time; ratings or postponement are common considerations.
Recent high-grade glioma or glioblastoma; active radiation/chemotherapy — Generally decline/postpone for traditional fully underwritten life insurance.
Brain metastasis or recurrent/progressive CNS malignancy — Generally not a traditional fully underwritten opportunity while metastatic/progressive disease is present.

Do not start with "brain cancer." First determine whether the lesion is actually malignant. Many meningiomas, vestibular schwannomas and pituitary-region tumors are noncancerous. If it is a glioma, obtain the WHO grade and molecular diagnosis. If it is a metastasis, identify the primary cancer. The label changes the entire underwriting pathway.

The Advisor's Brain-Tumor Checklist

Exact diagnosis and pathology: meningioma, vestibular schwannoma, PitNET, astrocytoma, oligodendroglioma, glioblastoma, metastasis or other
WHO grade or other formal classification
Date of diagnosis and how the tumor was discovered: incidental imaging vs symptoms
Tumor size and precise location
Original pathology report and molecular testing, including IDH and 1p/19q when relevant
Operative report: gross-total resection, subtotal resection or biopsy only
Postoperative MRI and most recent MRI/CT; include at least two comparison studies when possible
Any known residual tumor and whether it has grown
Radiation/radiosurgery, chemotherapy, temozolomide, targeted therapy or other treatment with dates
Any recurrence, progression, additional surgery or planned treatment
Seizure history, date of last seizure, antiseizure medication and driving status
Neurological residuals: weakness, speech/cognition, headaches, hydrocephalus, visual-field deficits, hearing, balance or facial nerve problems
For pituitary tumors: hormone secretion, replacement therapy, visual fields and endocrine control
For vestibular schwannoma: unilateral vs bilateral and any NF2-related schwannomatosis evaluation
Most recent neurology/neurosurgery/neuro-oncology assessment and next planned imaging/follow-up

Bottom Line for Advisors

Brain-tumor underwriting begins with pathology and imaging, not the generic diagnosis. A favorable submission can often be summarized in one sentence: "WHO Grade 1 meningioma, gross-total resection four years ago, no seizures or neurological deficits, serial MRIs show no recurrence." That is dramatically more useful than "history of brain tumor."

Sources

National Cancer Institute (NCI), Adult Central Nervous System Tumors Treatment (Patient and Health Professional PDQ)
National Cancer Institute (NCI-CONNECT), "Meningioma: Diagnosis and Treatment"
National Cancer Institute (NCI), Central Nervous System Tumors Treatment (Health Professional PDQ)
National Cancer Institute (NCI-CONNECT), "Oligodendroglioma and Other IDH-Mutated Tumors"
NIH/NIDCD, "Vestibular Schwannoma (Acoustic Neuroma) and Neurofibromatosis"
Munich Re, "From Benign to Malignant: The Arrival of Pituitary Neuroendocrine Tumors (PitNETs)," March 2024
Pacific Life, current public Impairment Guide (PLF4249, 2025/2026)
NAILBA, Field Underwriting Guide, Version 4.0 (2018), Epilepsy/Seizures
Principal Life Insurance Company, public Life Insurance Underwriting Guide

This article is educational only and is not medical, legal, tax or insurance advice. It is not an offer, quote or promise of eligibility or rate class. Underwriting guidelines, reinsurance practices, products and pricing vary by insurer, jurisdiction, age and individual facts and can change without notice. The issuing carrier makes the final underwriting decision. Applicants should answer all questions completely and truthfully and make medical decisions with licensed healthcare professionals.

Brain Tumors and Life Insurance Underwriting